Court Allows Derivative Shareholder Suit Against Pfizer to Move Forward

A federal district court judge has denied Pfizer’s motion to dismiss a derivative shareholder suit against the company which alleges that directors and executives at Pfizer are liable for actions that led to a historic $2.3 billion settlement with the U.S. government in 2009.  Pfizer entered into this enormous settlement to resolve allegations under the federal False Claims Act and Anti-kickback Statute for alleged “off-label promotion” of various drugs, including Bextra and Celebrex. The $2.3 billion settlement included a $1.195 billion criminal fine (largest ever in U.S. history), $105 million in criminal forfeitures, and a $1billion civil settlement (largest ever against a pharmaceutical company).

Shareholders filed a suit in November of 2009 in a district court of New York alleging that certain directors and executives were responsible to the shareholders due to the $2.3 billion settlement’s impact on shareholder profits.  The judge denied Pfizer’s motion to dismiss the case and stated that directors and executives “breached a fiduciary duty to Pfizer by causing or conscientiously disregarding the illegal marketing activity.”  While courts have long recognized that directors may be liable for a lack of oversight in theory, it usually requires something as egregious as outright embezzlement to break the fiduciary duty.  This court’s willingness to allow a derivative shareholder suit to progress based on a lack of compliance with federal regulations demonstrates that this court believes Pfizer’s lack of regulatory oversight far exceeded that of other companies who had these types of lawsuits dismissed.

Contact Information